Discontinue use if interstitial lung disease, ulcerative keratitis is confirmed. Severe or persistent diarrhoea, nausea, vomiting or anorexia; keratitis; CNS haemorrhages; GI perforation, underlying history of GI ulceration, smoking, bowel metastases at perforation sites. Assess EGFR mutation of tumour tissue prior to treatment. Periodically monitor liver function. Monitor patients w/ known CYP2D6 metaboliser genotype. Galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption. Concomitant use w/ CYP3A4 inducers & inhibitors, warfarin, proton-pump inhibitors, H2
-antagonists, vinorelbine, steroids, NSAIDs. May affect ability to drive & use machines. Renal impairment (CrCl <20 mL/min). Moderate to severe hepatic impairment. Women of childbearing potential. Not to be used during pregnancy & lactation. Childn & adolescents <18 yr.